Study of daratumumab, bortezomib, and dexamethasone for plasmablastic lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have plasmablastic lymphoma confirmed by biopsy, and the tumor must be CD38-positive (at least 5% of cells).
- Your lymphoma is relapsed or refractory after at least one standard chemotherapy treatment (with certain transplant situations allowed).
- You are at least 18 years old, and your daily functioning is not too limited (ECOG 0–3).
- You have at least one tumor area seen on scans that is big enough to measure.
- If you have HIV, it must be controlled with your current anti-HIV medicines (cART).
- If you can become pregnant (or you’re a man sexually active with a pregnancy-capable partner), you must use effective birth control for the required time after study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
This study tests an investigational drug called elranatamab to see if it can help keep plasmablastic lymphoma from coming back after you've finished your first treatment. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This trial tests a new drug called glofitamab combined with standard chemoimmunotherapy (called R-CHOP) for people with HIV-related large B-cell lymphoma that has not been treated before. The goal is to see if adding this drug improves outcomes and is safe.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This trial tests a new treatment plan for people newly diagnosed with primary plasma cell leukemia (pPCL). It uses two different drug combinations that include daratumumab, given one after the other, followed by maintenance daratumumab. The goal is to see if this approach is safe and works well.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.